Thomson Reuters Business Description
Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2011, the Company introduced a number of new drugs and formulations, such as Entavir (entecavir tablets), an antiviral for hepatitis B; Febucip (febuxostat tablets), a drug for gout; Flosoft (fluorometholone acetate ophthalmic suspension), a topical steroid for eye inflammation; Foracort (formoterol and budesonide autohaler), an asthma controller therapy in a new easy-to-use breath actuated inhaler; Furamist AZ (fluticasone furoate and azelastine hydrochloride nasal spray), a nasal spray for allergic rhinitis, and Montair FX (montelukast and fexofenadine tablets), an antiallergic combination for rhinitis. In April 2010, it commenced commercial production of pharmaceutical formulations at its Special Economic Zone project at Indore, Madhya Pradesh. It includes facilities for the manufacture of aerosols, liquid orals, pre-filled syringes, nasal sprays, eye drops, tablets and capsules.
